事業成果物：
研究成果は、国内外の学会などに報告し、あるいは原著論文として論文発表を行った。学会発表などは省略し、英文原著論文のみを記載する。

1．Lee J, Mashima T, Kawata N, Yamamoto N, Morino S, Inaba S, Nakamura A, Kumagai K, Wakatsuki T, Takeuchi K, Yamaguchi K, Seimiya H. Pharmacologic targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer.
Cancer Res. Commun., 2024 May 20;4(5):1307-1320. doi: 10.1158/2767-9764.CRC-23-0639.

2．Nakamura A, Mashima T, Lee J, Inaba S, Kawata N, Morino S, Kumagai K, Yamaguchi K, Seimiya H. Intratumor transforming growth factor-β signaling with extracellular matrix-related gene regulation marks chemotherapy-resistant gastric cancer.
Biochem. Biophys. Res. Commun., 2024 Aug 20;721:150108. doi: 10.1016/j.bbrc.2024.150108.

3．Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, Migita T, Seimiya H. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma.
Cancer Sci., 2024 Mar;115(3): 791-803. doi: 10.1111/cas.16073.

4．Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
Cancer Lett., 2024 Mar 1;584: 216632. doi: 10.1016/j.canlet.2024.216632.

5．Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Br. J. Cancer., 2024 Jan;130(1): 151-162. doi: 10.1038/s41416-023-02484-8.

6．Utsumi T, Mizuta H, Seto Y, Uchibori K, Nishio M, Okamoto I, Katayama R. AXL-mediated drug resistance in ALK-rearranged NSCLC enhanced by GAS6 from macrophages and MMP11 positive fibroblasts.
Cancer Sci., In press,2025 Feb 4. doi: 10.1111/cas.70006.

7．Maruyama K, Shimizu Y, Nomura Y, Oh-hara T, Takahashi Y, Nagayama S, Fujita N, Katayama R. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.
NPJ Precis. Oncol., 2025 Jan 6;9(1):4. doi: 10.1038/s41698-024-00793-6.

8．Wei X, Uchibori K, Kondo N, Utsumi T, Takemoto A, Koike S, Takagi S, Yanagitani N, Nishio M, Katayama R. MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Cancer Lett., 2024 Nov 1;604:217220. doi: 10.1016/j.canlet.2024.217220.

9．Shiraishi A, Oh-Hara T, Takahashi Y, Uchibori K, Nishio M, Katayama R. 3D layered co-culture model enhances trastuzumab deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
Biochem. Biophys. Res. Commun., 2024 Jun 11;725:150255. doi:10.1016/j.bbrc.2024.150255.

10．Shirahama H, Tani Y, Tsukahara S, Okamoto Y, Hasebe A, Noda T, Ando S, Ushijima M, Matsuura M, Tomida A. Induction of stearoyl-CoA desaturase confers cell density-dependent ferroptosis resistance in melanoma.
J. Cell. Biochem., 2024 Apr;125(4):e3054274. doi: 10.1002/jcb.30542.

11．Takagi S, Nakajima M, Koike S, Takami M, Sugiura Y, Sakata S, Baba S, Takemoto A, Saito M, Funauchi Y, Ae K, Takeuchi K, Fujita N, Katayama R. Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma.
Oncogene, 2025 Apr;44(12):794-804. doi: 10.1038/s41388-024-03251-6.

12．Watanabe K, Yamamoto T, Fujita T, Hino S, Hino Y, Yamazaki K, Ohashi Y, Sakuraba S, Kono H, Nakao M, Ochiai K, Dan S, Saitoh N. Metabolically inducing defects in DNA repair sensitizes BRCA-wild-type cancer cells to replication stress.
Sci. Signal., 2024 Nov 12;17(862): eadl6445. doi: 10.1126/scisignal.adl6445.

13．Takeuchi K, Nishimura Y, Matsubara T, Isoyama S, Suzuki A, Matsuura M, Dan S. Prediction of cell cycle distribution after drug exposure by high content imaging analysis using low-toxic DNA staining dye.
Pharmacol. Res. Perspect., 2024 Jun;12(3):e1203. doi: 10.1002/prp2.1203.

報告書

事業成果物名	腫瘍細胞社会の構築機構解明と新世代がん治療薬の開発
ファイル	形式：PDF　容量：88KB
事業成果物名	腫瘍細胞社会の構築機構解明と新世代がん治療薬の開発
URL	https://nippon.zaidan.info/nf_lib/nf_libServlet/nf_lib1050?np=1019&jigyo_id=0000100833